(Finance) – Great day for DiaSorinwhich is marking a rise of 2.03%.
The Italian diagnostic company announced the CE marking of the Aries Flu A / B & RSV + SARS-CoV-2 test for the identification and differentiation of the four most common respiratory viruses and the infections they generate. The test – reads a note – will be executable on the Aries molecular diagnostic platform and will offer clinical laboratories a fully automated diagnostic solution capable of providing useful results efficiently and with minimal intervention time by the operators.
“Our new test will allow hospitals and clinical laboratories to adopt a flexible and scalable diagnostic approach, expanding clinical investigation to the four most relevant viral targets for pediatric and adult patients in the flu season,” he points out. Angelo Rago, president of Luminex, a company of the DiaSorin group.
The Diasorin stock is promoted by analysts of Equity which confirm the “buy” recommendation and target price of 160 euros.
Comparing the performance of the stock with the FTSE MIBon a weekly basis, it is noted that themanufacturer of diagnostic equipment maintains positive relative strength in comparison with the index, demonstrating greater appreciation by investors compared to the index itself (weekly performance + 7.64%, compared to + 4.03% of the main index of the Milan Stock Exchange).
The study of DiaSorin shows a weakening of the trendline at the bottom test seen at 118.1 Euro. In the presence of positive ideas, the trend is towards a push up to the top 121.8. The forecasts are for a continuation of the negative trend towards the 115.7 support.